Section Arrow
VTRS.NASDAQ
- Viatris
Quotes are at least 15-min delayed:2026/11/14 14:16 EST
Regular Hours
Last
 20.82
+0.15 (+0.73%)
Day High 
20.865 
Prev. Close
20.67 
1-M High
21.2 
Volume 
6.51M 
Bid
20.4
Ask
20.8
Day Low
20.385 
Open
20.77 
1-M Low
17.205 
Market Cap 
23.70B 
Currency 美元 
P/E -- 
%Yield 2.88 
10-SMA 19.78 
20-SMA 19.16 
50-SMA 18.03 
52-W High 21.2 
52-W Low 10.15 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.53/2.71
Enterprise Value
36.36B
Balance Sheet
Book Value Per Share
11.94
Cash Flow
Cash Flow Yield
0.10
Income Statement
Total Revenue
14.74B
Operating Revenue Per Share
13.49
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
AKANAkanda Corp.1.36+0.6883+102.47%-- 
HLNHaleon plc9.17+0.08+0.88%18.97PE
HIMSHims & Hers Health19.73------ 
TEVATeva Pharmaceutical Industries Limited44.5+0.85+1.95%102.3PE
VTRSViatris20.82+0.15+0.73%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up one-third of Viatris' total sales. The remaining sales are derived from its portfolio of legacy products, including Lipitor, Norvasc, Lyrica, and Viagra.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.